<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355874</url>
  </required_header>
  <id_info>
    <org_study_id>VEN 309-Hem-SE3-001</org_study_id>
    <nct_id>NCT01355874</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids</brief_title>
  <acronym>VEN309</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Intra-Anal Application of Iferanserin (10 mg) as a 0.5% Ointment in Subjects With Symptomatic Internal Hemorrhoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ventrus Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ventrus Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the effect of iferanserin ointment on cessation of bleeding when administered&#xD;
      intra-anally twice daily (BID) for 7 or 14 days in subjects with symptomatic internal&#xD;
      hemorrhoids.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Double-Blind: Phase 3, multicenter, double-blind, randomized, parallel group,&#xD;
      placebo-controlled part of the study. Extension: Multicenter, open-label part of the study.&#xD;
&#xD;
      Study Treatment Duration:&#xD;
&#xD;
      Double-Blind: 28 days (14-day treatment period and a 14-day follow-up period). Extension: 12&#xD;
      months (open-label part of the study in which there will be a scheduled visit every three&#xD;
      months. Subjects who have recurrence(s) of their symptomatic internal hemorrhoids will be&#xD;
      treated with open-label iferanserin for 7 days followed by a 21-day follow-up period).&#xD;
&#xD;
      Criteria for Evaluation:&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      The primary endpoint is the cessation of bleeding by the end of Day 7 that persists for the&#xD;
      remainder of the treatment period (through Day 14).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the effect of iferanserin ointment on cessation of bleeding when administered&#xD;
      intra-anally twice daily (BID) for 7 or 14 days in subjects with symptomatic internal&#xD;
      hemorrhoids. Safety Secondary Objective To determine the safety of iferanserin ointment&#xD;
      administered intra-anally BID for 7 or 14 days in subjects with symptomatic internal&#xD;
      hemorrhoids.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
      To evaluate the frequency of recurrence of bleeding in subjects with symptomatic internal&#xD;
      hemorrhoids. To evaluate time to bleeding recurrence in subjects with symptomatic internal&#xD;
      hemorrhoids. To evaluate efficacy of iferanserin ointment in the treatment of recurrence when&#xD;
      administered intra-anally BID for 7 days in subjects with symptomatic internal hemorrhoids.&#xD;
      To evaluate the parameters of the Symptom Satisfaction Questionnaire&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Double-Blind: Phase 3, multicenter, double-blind, randomized, parallel group,&#xD;
      placebo-controlled part of the study. Extension: Multicenter, open-label part of the study.&#xD;
&#xD;
      Criteria for Evaluation:&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      The primary endpoint is the cessation of bleeding by the end of Day 7 that persists for the&#xD;
      remainder of the treatment period (through Day 14).&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
      Key Secondary Endpoints Cessation of itching by the end of Day 7 that persists for the&#xD;
      remainder of the treatment period (through Day 14). Cessation of pain by the end of Day 7&#xD;
      that persists for the remainder of the treatment period (through Day 14). Safety Secondary&#xD;
      Endpoints Adverse events (AEs). Serious Adverse events (SAEs). Physical examination.&#xD;
      Hematology, serum chemistry, and urinalysis. Vital signs. Electrocardiogram.&#xD;
&#xD;
      Exploratory Endpoints:&#xD;
&#xD;
      Bleeding recurrence rate of symptomatic internal hemorrhoids. Time to bleeding recurrence of&#xD;
      symptomatic internal hemorrhoids. Response to open-label iferanserin ointment in the&#xD;
      treatment of recurrence of symptomatic internal hemorrhoids. Overall improvement score for&#xD;
      the parameters of the Symptom Satisfaction Questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The primary endpoint was not met on the double blind data&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with cessation of bleeding by the end of Day 7 that persists for the remainder of the treatment period (through Day 14) will be analyzed as the primary endpoint</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with cessation of pain by the end of Day 7 that persists for the remainder of the treatment period (through Day 14).</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Internal Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Iferanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iferanserin + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iferanserin</intervention_name>
    <description>0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.</description>
    <arm_group_label>Iferanserin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ointment BID for 14 days during double blind.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iferanserin + Placebo</intervention_name>
    <description>0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.</description>
    <arm_group_label>Iferanserin + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1.1 Inclusion Criteria for Double-Blind and Recurrence&#xD;
&#xD;
          1. Males or non-pregnant females, aged ≥ 18 to ≤ 75 years.&#xD;
&#xD;
          2. Symptomatic internal hemorrhoids, Grades I-III by direct anoscopic visualization&#xD;
             (anoscopic visualization not required if Grade determined by colonoscopy within 28&#xD;
             days prior to Day 1).&#xD;
&#xD;
          3. Bleeding from hemorrhoids for two consecutive days prior to randomization (Day 1).&#xD;
&#xD;
             • For females experiencing menses, on the two days prior to randomization they must&#xD;
             confirm that blood is from the anus and not from their menses by gently inserting a&#xD;
             cotton swab into the anus after attempting a bowel movement; and they must see blood&#xD;
             on the cotton swab for the two consecutive days prior to randomization to meet the&#xD;
             inclusion criteria.&#xD;
&#xD;
          4. Itching OR pain for two consecutive days prior to randomization (Day 1).&#xD;
&#xD;
          5. Able to attempt bowel movements daily (defined as trying to have a bowel movement&#xD;
             while sitting on the toilet for at least a few minutes, at least once daily, whether&#xD;
             or not you feel the need to have a bowel movement that day).&#xD;
&#xD;
          6. Body mass index of ≥ 18.5 to ≤ 36 kg/m2.&#xD;
&#xD;
          7. Female of non-childbearing potential, including any female who: a) has had a&#xD;
             hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal&#xD;
             ligation or d) is post menopausal (demonstration of total cessation of menses for ≥ 1&#xD;
             year from the date of the screening visit).&#xD;
&#xD;
          8. Females of child bearing potential who agree to use two forms of contraception, one of&#xD;
             which must be a barrier method, during the full duration of the study.&#xD;
&#xD;
          9. Able to communicate adequately with the investigator and to comply with the&#xD;
             requirements for the entire study.&#xD;
&#xD;
         10. Capable of using the IVRS and adequately communicate comprehension of IVRS questions&#xD;
             to the investigator.&#xD;
&#xD;
         11. Capable of and freely willing to provide written informed consent prior to&#xD;
             participating in the study.&#xD;
&#xD;
        1. 1.2 Exclusion Criteria for Double-Blind and Recurrence&#xD;
&#xD;
          1. Grade IV internal hemorrhoids.&#xD;
&#xD;
          2. Age ≥ 40 years, with no complete colon evaluation within three years.&#xD;
&#xD;
          3. Age &lt; 40 years, with no sigmoidoscopy or complete colon evaluation within three years.&#xD;
&#xD;
          4. Age &lt; 40 years, with any of the following and no complete colon evaluation within two&#xD;
             years; or age ≥ 40 years, with any of the following and no complete colon evaluation&#xD;
             within one year:&#xD;
&#xD;
               -  History of adenomatous polyps.&#xD;
&#xD;
               -  Family history of either colorectal cancer or colorectal adenomas diagnosed in a&#xD;
                  first-degree relative before age 60.&#xD;
&#xD;
               -  Family history or genetic testing indicating the presence of one of two&#xD;
                  hereditary syndromes.&#xD;
&#xD;
          5. Malignancy within 5 years prior to Day 1(with the exception of treated basal&#xD;
             cell/squamous cell carcinoma of the skin).&#xD;
&#xD;
          6. History of inflammatory bowel disease.&#xD;
&#xD;
          7. History of irritable bowel syndrome with constipation or diarrhea.&#xD;
&#xD;
          8. Previous surgical or instrumental treatment of internal hemorrhoids.&#xD;
&#xD;
          9. Clinical evidence or history of fecal incontinence.&#xD;
&#xD;
         10. Current thrombosed internal or external hemorrhoid(s).&#xD;
&#xD;
         11. Clinical evidence or history of anal fissure.&#xD;
&#xD;
         12. Clinical evidence or history of anal fistula.&#xD;
&#xD;
         13. AST/ALT &gt; 3x ULN.&#xD;
&#xD;
         14. Hemoglobin &lt; 10.0 g/dL.&#xD;
&#xD;
         15. Selective serotonin reuptake inhibitors within 28 days prior to Day 1.&#xD;
&#xD;
         16. Tamoxifen within 28 days prior to Day 1.&#xD;
&#xD;
         17. Laxatives (unless maintained on a stable dose of the medication for ≥ 60 days prior to&#xD;
             Day 1).&#xD;
&#xD;
         18. Anticoagulants (e.g., coumadin, heparinoids, dabigatran) within 90 days prior to Day&#xD;
             1.&#xD;
&#xD;
         19. Anti-platelet agents or low dose aspirin (unless maintained on the medication for ≥ 90&#xD;
             days prior to Day 1).&#xD;
&#xD;
         20. Over the counter or prescription anti-hemorrhoid agents (including herbal supplements)&#xD;
             within 14 days prior to Day 1.&#xD;
&#xD;
         21. Topical anesthetics within 14 days prior to Day 1.&#xD;
&#xD;
         22. Chronic use of analgesics (e.g., opioids, acetaminophen, aspirin, NSAIDS, cox-2&#xD;
             inhibitors, etc).&#xD;
&#xD;
         23. Any investigational agents within 28 days prior to Day 1 (with the exception of&#xD;
             iferanserin for recurrence).&#xD;
&#xD;
         24. Anti-TNF agents within 6 months prior to Day 1.&#xD;
&#xD;
         25. Oral or parenteral steroids within 28 days prior to Day 1.&#xD;
&#xD;
         26. Use of anal, intra-anal, or intra-rectal steroids within 28 days prior to Day 1.&#xD;
&#xD;
         27. Expected to have a planned interventional and/or surgical procedure that requires&#xD;
             hospitalization, colonoscopy, or sigmoidoscopy (colonoscopy or sigmoidoscopy during&#xD;
             the screening period is acceptable).&#xD;
&#xD;
         28. Following concomitant disease state:&#xD;
&#xD;
               -  Clinical evidence or history of significant cardiovascular disease including&#xD;
                  arrhythmias, clinically significant ECG abnormalities, myocardial infarction,&#xD;
                  stroke, congestive heart failure (greater than class II), and valve disease or&#xD;
                  abnormalities.&#xD;
&#xD;
               -  Asthma currently requiring treatment (with the exception of infrequent use of&#xD;
                  rescue inhaler).&#xD;
&#xD;
               -  Clinical evidence or history of chronic renal failure (greater than Stage III).&#xD;
&#xD;
               -  Clinical evidence or history of gastric ulcer, duodenal ulcer, or pancreatitis.&#xD;
&#xD;
               -  Clinical evidence or history of hematological disease.&#xD;
&#xD;
               -  Clinical evidence or history of neurological disease.&#xD;
&#xD;
               -  Acute infection currently requiring treatment.&#xD;
&#xD;
               -  Clinical evidence or history of chronic infectious disease.&#xD;
&#xD;
         29. Major organ transplant.&#xD;
&#xD;
         30. Any disease or prior surgery that may interfere with the subject successfully&#xD;
             completing the study.&#xD;
&#xD;
         31. History of any prior anal or rectal surgery (hemorrhoid banding with the 5 years of&#xD;
             Day 1).&#xD;
&#xD;
         32. Psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt or&#xD;
             suicidal ideation, or any other psychiatric illness (with the exception of&#xD;
             intermittent anxiety).&#xD;
&#xD;
         33. Known sensitivity to investigational product(s) or class of investigational&#xD;
             product(s).&#xD;
&#xD;
         34. Drug or alcohol abuse within 12 months of Day 1.&#xD;
&#xD;
         35. Currently using narcotic(s) chronically.&#xD;
&#xD;
         36. Breast-feeding females.&#xD;
&#xD;
         37. Females on their menstrual cycle who cannot discern whether the bleeding is rectal&#xD;
             bleeding or vaginal bleeding from menstruation.&#xD;
&#xD;
         38. Employees, family members, or students of the investigator or clinical site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cleveland Clinic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Weston, FL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Health Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adobe</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Sun Clin Res</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR Gastro</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRI</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clin Res</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Orange County Surgical Group</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrence C. R.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Clin Res</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facey Med Foundation</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futura Research</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clin Trials</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Carmen Med Center</name>
      <address>
        <city>Reseda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MARG</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Res</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Research</name>
      <address>
        <city>Salida</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clin Res</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern</name>
      <address>
        <city>Hilieah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for GI Disorders</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clin Res</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jupiter Research</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aplusresearch</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRA</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Gastro Assoc</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICR</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast REgional Research Group</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri County</name>
      <address>
        <city>Hartwell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Med Inst</name>
      <address>
        <city>Overland</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucy med Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praetorian Pharmaceutical Res</name>
      <address>
        <city>Marrerro</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Mgmt</name>
      <address>
        <city>Metarie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women Under Study</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Digestive</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meritus Center for Clin Res</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Res Center</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saginaw Med Res</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Assoc Western Michigan</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Center for Clin Res</name>
      <address>
        <city>Lee's Summitt</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive &amp; Liver Diseases</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clin Res Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Jersey Gastro</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island GI Group</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRA NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashville Gastro</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Res Ass</name>
      <address>
        <city>Davidson</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital</name>
      <address>
        <city>Greenboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Research</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Res</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hightop Med Res</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Gastro</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastro</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinsearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastro</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assoc of Gastro</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dial Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amcare Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Gastro</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Permian</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARI</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARI</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New River Valley Res</name>
      <address>
        <city>Christianburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Medical Center</name>
      <address>
        <city>Lyncburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ventrusbio.com</url>
    <description>Ventrus Biosciences Home Page</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <last_update_submitted>January 26, 2014</last_update_submitted>
  <last_update_submitted_qc>January 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Internal Symptomatic Hemorrhoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 6, 2014</submitted>
    <returned>April 24, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

